A recent report by de Lima and coworkers showed that intravenous busulfan administered once daily over 4 days together with fludarabine can be used successfully as the preparative regimen before allogeneic hematopoietic cell transplantation from matched sibling and unrelated donors.
1 Besides the positive outcome of their study, they showed that the once-daily infusion of busulfan was associated with low interdose variation of busulfan plasma pharmacokinetics (PK) and no accumulation over the 4 days of administration. Although interdosing variability was minimal, the daily area under the concentrationtime curve (AUC) ranged between 2931 and 8271 mmol min. Targeting of oral busulfan has been associated with favorable clinical results and reduced toxicity in patients receiving allogeneic transplantation for CML and MDS.
2,3 We therefore performed a pilot study in 10 patients with hematological malignancies combining 30 mg/m 2 fludarabine i.v. (day À9 to À6) over 4 days with single doses of intravenous busulfan infused over 2 h on four consecutive days (À5 to À2). The starting dose of busulfan administered was 3.3 mg/kg adjusted to ideal body weight. We used a DMSO-based formulation which has been described in previous dose-finding studies.
4 Blood samples were drawn every day during busulfan administration at time-points 0, 1, 2 (end of infusion), 3, 4 and 6 h. The busulfan plasma concentration was determined by HPLC. 5 The dose of busulfan was targeted to achieve a concentration at steady state (Css) of 800-1000 ng/ml on the subsequent day. This target corresponded to AUC values of 4677-5847 mmol min/l after daily single doses of busulfan, and was equivalent to the Css target used in a recent clinical study with fludarabine and oral busulfan.
6 Figure 1 summarizes the doses of busulfan administered on each day and the corresponding plasma levels achieved. Three patients had a coefficient of variation of 425%, requiring more rigorous dose modifications. One of these patients had an elevated creatinin which dropped after infusion therapy. Minor dose modifications were required on the third and fourth days of busulfan application in all cases. Table 1 shows the PK parameters achieved with our approach. After transplantation of G-CSF-mobilized blood, GvHD prophylaxis consisted of tacrolimus 0.03 mg/kg and mycophenolate mofetil 2 Â 1.5 g. Primary graft failure occurred in one patient only. He died after a second transplant from a mismatched sibling donor. Grade 4 hyperbilirubinemia associated with sepsis from Escherichia coli was observed in one patient who subsequently succumbed with multiorgan failure. No additional case of grade 4 extramedullary toxicity was observed. Relapse of high-risk acute myeloid leukemia occurred in two cases. Six patients are alive between 120 and 380 days after transplantation without signs of active disease. Our preliminary findings suggest that targeting of single-dose intravenous busulfan using a limited sampling strategy might allow to achieve a lower interpatient variability than reported by de Lima and coworkers.
1 Of course the ideal target dose in this setting has not been defined yet. Prospective studies are warranted to prove whether the target level of once-daily intravenous busulfan, as described here, offers a meaningful clinical benefit compared to the standard split-dose application. 
